Baricitinib in Dermatology: Expanding Therapeutic Horizons Beyond Alopecia Areata

Baricitinib, a first-generation JAK inhibitor, has shown significant promise in dermatology, particularly for treating moderate to severe alopecia areata (AA) and atopic dermatitis (AD), following its FDA approval in June 2022. The drug's efficacy extends to other refractory conditions like vitiligo and dermatomyositis, although more research is needed to confirm these findings. Its use during the COVID-19 pandemic highlighted its antiviral and anti-inflammatory benefits. Baricitinib's expanding role in managing immune-mediated skin diseases emphasizes the need for ongoing research to refine dosing, assess long-term safety, and explore its potential in a wider range of inflammatory dermatoses.